Jonathan Montagu is the co-founder and CEO of HotSpot Therapeutics, a Boston biotech he started in 2017 to chase what the industry long called undruggable. His bet: target the 'natural hotspots' that evolution built into proteins to switch them on and off, and you can make small-molecule medicines with precision the old playbook couldn't reach. A chemist trained at Oxford, Scripps and Cancer Research UK with a Stanford MBA, he previously did the dealmaking that put Nimbus Therapeutics and Concert Pharmaceuticals on the map, including a $1B GSK transaction. Under him HotSpot has raised roughly $210M and pushed its Smart Allostery platform into the clinic, presenting first-in-human Phase 1 data on its CBL-B inhibitor HST-1011 at ESMO 2024.
Gordon Earle Moore (1929-2023) was the co-founder and emeritus chairman of Intel Corporation, and the visionary behind Moore's Law - the observation that the number of transistors on integrated circuits doubles approximately every two years. A chemist and physicist by training, Moore was one of the 'Traitorous Eight' who left Shockley Semiconductor to found Fairchild Semiconductor in 1957, then co-founded Intel in 1968 with Robert Noyce. His 1965 prediction became the guiding principle of the semiconductor industry and fueled the digital revolution. Beyond technology, Moore and his wife Betty donated over $10 billion through their foundation to environmental conservation, scientific research, and patient care, making him one of the most generous philanthropists in history.